bluuebunny/crossref_metadata_2025_split huggingface dataset:
NCMP-18. A CASE OF METASTATIC GLIOBLASTOMA MULTIFORME
Authors: Boldig Catherine , Pina Yolanda , Etame Arnold 
Published: November 2024

Abstract
Glioblastoma multiforme (GBM) is the most common primary brain tumor and rarely causes metastasis. We present a case of a 43-year-old female who developed tingling and heaviness in her right lower extremity in March 2023. This sensation progressed to involve her entire right hemi-body over the next two months. She presented to the emergency department where an MRI show a large left frontal parietal mass measuring 5.2x3.7x3.7cm with significant mass effect. She underwent surgical resection and surgical pathology showed IDH1-mutant R132H, retained ATRX, MGMT promoter mutation, and ki-67 of 80%. She received 6 weeks chemoradiation and then started maintenance temozolomide at 150mg/m2. Temozolomide was increased to 200mg/m2 for cycle 3 maintenance. In March 2024, she presented to the hospital with pain radiating down her legs and saddle anesthesia. MRI lumbar spine showed infiltrating osseous mass at S1 and S2 and bilateral sacral ala with anterior and posterior extraosseous invasion, invading the spinal canal resulting in moderate to severe spinal canal narrowing and compression of the sacral nerve roots. She underwent biopsy of the lesion which showed IDH wildtype metastatic GBM. She also underwent lumbar puncture and cerebrospinal fluid cytology was negative. She experienced pancytopenia limiting chemotherapy options. In April 2024, she underwent PET scan which showed hypermetabolic epidural soft tissue in spinal canal at L5-S1 level, widespread hypermetabolic skeletal lesions, tiny left cervical level 4 lymph node, small hypermetabolic right hilar, aortocaval, left retroperitoneal nodes and a tiny left common iliac node. The incidence of extracranial metastasis is 0.4-2.0% with less than 25 reported cases of bone marrow spread. This is thought to be rare due to the absence of lymphatics within the brain and the limited survival associated with GBM. This metastasis may occur through vascular invasion, perineural spread, lymphatics, direct invasion, or iatrogenic spread into soft tissues.
NCMP-19. IMPACT OF SUBVENTRICULAR ZONE INVASION ON PREOPERATIVE COGNITIVE DECLINE IN DIFFUSE GLIOMA PATIENTS
Authors: Chen Ko-Ting , Li Hsin-Ya , Lao Ian-Hou , Chen Yi-Chun , Wu Yah-Yuan , Chu Yi-Chuan , Wei Kuo-Chen , Chen Pin-Yuan , Chang Wei-Han 
Published: November 2024

Abstract

PURPOSE
To determine the impact of subventricular zone (SVZ) invasion on neurocognitive dysfunction in diffuse glioma patients.

MATERIALS AND METHODS
We collected neuropsychological assessments of treatment-naïve WHO grade 2-4 diffuse glioma patients between 2017 to 2023. The Chi-square test determined the odds ratio (OR), and multiple linear regression identified factors related to cognitive deficits using Python 3.11.4.

RESULTS
Of the 129 patients, 64 exhibited SVZ invasion (SVZ+) while 65 were SVZ-. Groups were matched for WHO grading. SVZ+ was associated with more defective domains than SVZ- in both lower grade (WHO grade 2,3, 3.2 ± 2.1 vs. 2.1 ± 1.9, p=0.019) and high grade (WHO grade 4, 4.9 ± 1.6 vs. 3.6 ± 2.2, p=0.019) tumors. In lower grade gliomas, SVZ+ increased risks of language (OR 7.500, p&lt;0.001) and visual learning impairments (OR 4.375, p=0.014). In high grade gliomas, SVZ+ rendered greater language (OR 8.556, p=0.003) and auditory learning vulnerability (OR 3.850, p=0.039). In right hemispheric tumors, SVZ+ lesions conferred worse executive (OR 6.667, p=0.006) and language function (OR 9.063, p=0.017); in left hemispheric tumors, SVZ+ lesions increased language (OR 3.125, p=0.012) and auditory learning (OR 2.889, p=0.024) impairment. Frontal horn of SVZ+ was related to working memory decline, and body part of SVZ+ was related to emotional deficits. Age and WHO grade 4 were associate with more defective domains in the SVZ+ group. In the SVZ- group, parietal lobe tumor was associate with more defective domains, while high education, temporal lobe, and WHO grade 2 were associate with fewer defective domains.

CONCLUSION
SVZ invasion impacts pre-operative neurocognitive function regardless of lesion laterality and WHO grade. Distinct SVZ sub-regions are linked to specific cognitive impairments. These findings highlight the need for precise tumor mapping involving the SVZ to evaluate neurocognitive outcomes and consider preventive or rehabilitative interventions.
NCMP-23. PATIENTS WITH BRAIN TUMORS HAVE DECREASED BILATERAL FINGER DEXTERITY COMPARED TO HEALTHY ADULTS
Authors: Conway Brian , Taquet Léon , Boerger Timothy , Goetschel Kaitlin , Tarima Sergey , Schmit Brian , Krucoff Max 
Published: November 2024

Abstract
Unilateral brain tumors are known to affect motor control of the contralateral hemibody, but ipsilesional effects are less frequently studied and may be just as impactful to quality of life. Hand dexterity, for example, is a critical skill that often requires both hands. Here, a cohort of 15 patients with unilateral brain tumors and 47 healthy adults performed individual finger movements with each finger (except the thumb) on each hand while tracked by a data glove (Cyberglove III, CyberGlove Systems, San Jose, CA). The ability to move each finger independently was quantified using a scale previously developed by our lab (individuation score) that represents dexterous ability. Repeated-measures two-way ANOVA with factors of group (brain tumor vs. healthy) and laterality (contralesional vs. ipsilesional) were performed for each finger. The lesional side was set to the left brain for cases in the brain tumor group for simplicity of analysis. There was a significant main effect of “group” for all finger individuation scores (index p-value&lt;0.0001, middle p-value&lt;0.0001, ring p-value&lt;0.001, small p-value&lt;0.01) with healthy volunteers scoring higher than patients. There was no main effect of “laterality.” Group-laterality interaction effects were not significant except for the small finger where healthy adults’ right but not left sided individuation scores were greater than the brain tumor group’s (p-value&lt;0.01). Additionally, using cluster analysis incorporating data from both hands, we were able to differentiate patients with brain tumors from healthy adults with 97.9% specificity, 60% sensitivity, 90% positive predictive value, and 88.5% negative predictive value. Ultimately, these results suggest that unilateral brain tumors decrease hand dexterity bilaterally without a significant lateralizing difference except in the small finger. These results suggest unilateral lesions can have bihemispheric network effects, and/or that hand dexterity may rely on ipsilesional connections more than previously understood.
NCMP-26. PATIENTS WITH ANTI-HU/ANNA1 PARANEOPLASTIC NEUROLOGICAL DISORDERS DEVELOP PROGRESSIVE DISABILITY BUT HAVE INCREASED SURVIVAL
Authors: DiMauro Kimberly , Thompson Nicolas , Stevens Glen , Kunchok Amy 
Published: November 2024

Abstract

ANNA-1/Hu-IgG paraneoplastic neurological disorders (PND) are rare and factors associated with disability and survival outcomes are unknown. We aimed to 1) examine disability and survival in ANNA1/Hu-IgG PND and 2) compare survival to a control group of small cell lung cancer (SCLC) without PND.

METHODS
This is a retrospective cohort study of ANNA1/Hu-IgG+ with PND and a control cohort of SCLC without PND (n=1513). Cox proportional hazard models examined clinical predictors of disability and survival. Kaplan-Meier curves examined time to mortality and mRS&gt;2. Cox proportional hazard models compared survival between ANNA1/Hu-IgG PND and SCLC without PND, adjusting for age, sex, cancer stage, and brain metastases.

RESULTS
Forty-five patients with ANNA/Hu1-IgG PND were included (73% female, mean age=63 years [SD=13]). Phenotypes included; neuropathy (16, 36%), ataxia (11, 24%), encephalitis (10, 22%), myasthenic syndromes (3, 7%), myelopathy (2, 4%), enteric neuropathy (2, 4%), myoclonus (1, 2%). Cancers were identified in 78%; SCLC (26, 74%), non-SCLC (4, 11%), other (5, 14%). Immunosuppressive therapy for PND was given in 53%. At 5-year follow-up, 74% had mRS&gt;2. Limbic encephalitis had greater hazard of mRS&gt;2 at last follow-up (HR=7.76, [95% CI=2.20-27.39], p=0.001). At 5-year follow-up, 58% had died. Survival was not influenced by phenotype nor immunosuppressive treatment. Patients with SCLC and ANNA1/Hu-IgG (n=26) were compared to SCLC without PND (n=1513) and had 54% lower hazard of death (adjusted HR =0.46, [95% CI = 0.28–0.76], p=0.003). In ANNA-1/Hu-IgG PND, most patients experienced disability and greater disability was associated with limbic encephalitis, suggesting a potential modifiable factor. However, patients with SCLC and ANNA1/Hu-IgG PND survived longer than patients with SCLC without ANNA1/Hu-IgG PND, suggesting a possible survival advantage due to earlier cancer detection (lead time bias) and/or increased antitumor immunity.
NCMP-30. GLUCOCORTICOID-INDUCED HYPERGLYCEMIA IN BRAIN TUMOR PATIENTS: A SINGLE CENTER RETROSPECTIVE STUDY
Authors: Okoye Obiora , Hurst Katlyn , Corona-Macedo Brayan , Folarin Oluwamuyiwa , Jones Morgan , Kargi Atil , Rauf Yasmeen , Higgins Dominique 
Published: November 2024

Abstract

BACKGROUND
Glucocorticoid (GC) therapies are integral in managing brain tumor-associated cerebral edema and neurological deficits in the neuro-oncology perioperative setting. Despite their effectiveness, GCs can induce significant morbidity, including hyperglycemia.

METHODS
This single-center retrospective study at the University of North Carolina neurological surgery department examines the incidence and risk factors for glucocorticoid-induced hyperglycemia in brain tumor patients treated with high-dose GCs. Data from clinical databases, electronic medical records, laboratory systems, and pathology information banks will be utilized. Documented glucose measurements, glycated hemoglobin test (HbA1c) and clinical outcomes (mortality, infection, hypoglycemia) in brain cancer patients treated with Glucocorticoid (GC) that developed hyperglycemia will be compared with brain tumor patient with normoglycemia.

RESULTS
We will document the total number of brain tumor patients referred over the study period, eligibility rates, and the percentage that developed glucocorticoid-induced diabetes (defined as two glucose measurements ≥200 mg/dL within the first week of treatment). Timing of hyperglycemia onset, treatments received, and risk factors for developing glucocorticoid-induced diabetes will also be analyzed.

CONCLUSIONS
The findings could underscore the necessity for proactive screening for glucocorticoid-induced diabetes in brain tumor patients to mitigate the associated morbidity. This study may guide future research on the benefits of optimized glucose control on clinical outcomes in patients with GC-induced hyperglycemia. Keywords: brain tumor, steroid-induced hyperglycemia, glucocorticoid-induced diabetes, dysglycemia, risk factors, outcomes.
NCOG-02. ASSESSING THE INFLUENCE OF ADJUVANT INTERSTITIAL BRACHYTHERAPY ON MALIGNANT BRAIN TUMOR PATIENTS: INSIGHTS FROM THE NATIONAL READMISSION DATABASE
Authors: Sun Kevin , Zhu Ping , Do Truong , Chen Clark 
Published: November 2024

Abstract
Interstitial brachytherapy (IB) is a form of surgically administered radiotherapy involving the implant of radioactive seeds into the resection cavity after tumor excision. Advances in IB for brain cancers have revived interest in this treatment platform. However, the impact of this therapy on hospital quality measures remains poorly characterized. Here we utilized the National Readmission Database (NRD) to address this gap in knowledge. We identified patients with malignant brain tumors who had undergone either craniotomies (C) for tumor resection or craniotomies augmented with adjuvant interstitial brachytherapy (C+IB) in the National Readmission Database (NRD, 2010-2018). Propensity-score weighting and survey regression techniques were used for analysis. Over the study period, the number of craniotomies with adjuvant interstitial C+IB steadily decreased. For brain metastasis (BM) patients, C+IB and C patients exhibited comparable length of hospital stay (IRR:0.95, CI95:0.61-1.50, p=0.838) and routine discharge to home or self-care (OR:1.01, CI95:0.86-1.18, p=0.918). However, primary brain tumor (PBT) patients who underwent C+IB showed longer hospital stay (IRR:1.43, CI95:1.03-1.99, p=0.032) and are less likely to undergo routine discharge (OR: 0.38, CI95:0.20-0.74, p=0.005) relative to the C cohort. Despite these differences, C+IB and C patients showed comparable 30- or 90- day readmission risk. The profile of readmission diagnoses was also similar. Cost-analysis suggests that IB increased the median total charge by $19,184 (p=0.003). Our analysis suggests that adjuvant interstitial brachytherapy did not alter hospital course/readmission risk for brain metastasis patients. However, PBT patients who underwent this therapy showed longer hospitalization and increased likelihood for non-routine discharge.
NCOG-06. FACTORS ASSOCIATED WITH SOCIAL DISABILITY IN THE CHRONIC POSTOPERATIVE PERIOD IN PATIENTS WITH GLIOMAS
Authors: Nakajima Riho , Kinoshita Masashi , Okita Hirokazu , Nakada Mitsutoshi 
Published: November 2024

Abstract

BACKGROUND
Patients with low-grade gliomas may have no obvious problems during hospitalization or their initial return to social life; however, social life difficulties may gradually become more apparent long after the surgery. We investigated factors associated with social disabilities in patients with low-grade gliomas in the postoperative chronic phase.

METHODS
The study included 114 patients with WHO grade 2 or 3 gliomas who underwent surgery (mean age, 44.3±13.2 years). Seventy-six patients underwent an initial surgery and 38 underwent a second surgery. All patients underwent various brain functional assessments and interviews about their social lives over 1 year after the surgery (median, 23 months). Factors associated with social disabilities were determined using logistic multiple regression analysis and chi-square tests. Voxel-based lesion symptom mapping was used to examine the brain regions associated with social disabilities.

RESULTS
Social disabilities were observed in 12.3% of the patients. Factors associated with social disabilities were the number of surgeries (first vs. second, p=0.0052) and tumor location (left vs. right, p=0.0091). Patients with recurrence and right cerebral hemispheric lesions had a higher probability of social disability (42.1%, p&lt;0.0001) than that of other patients. The reasons for social disability after right hemispheric recurrence were social behavior disorder (62.5%) and neuropsychological dysfunctions (37.5%). Social behavioral disorders include interpersonal problems, such as job switching owing to problems with others, poor interpersonal relationships, and sexually deviant behavior. No other apparent neuropsychological abnormalities were found in patients with social behavior disorders. Surgical resection of the deep part of the right prefrontal area is associated with social behavior disorders and right supplementary motor cortex resection is associated with neuropsychological disorders.

CONCLUSION
In lower grade glioma, patients with right hemispheric recurrence were more likely to develop social disabilities in the chronic phase, which was caused by social behavioral disorders and neuropsychological dysfunctions.
NCOG-07. SAFETY OF ONC201 TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED H3 K27M-MUTANT GLIOMA: RESULTS FROM ONC028, AN ONGOING COMPASSIONATE USE PROGRAM
Authors: Sharma Akansha , Aiken Robert , Korones David N , Koschmann Carl , Lubes Jourdan , Gardner Sharon L , Morrison Marion , Ramage Samuel C , Tarapore Rohinton S , Odia Yazmin 
Published: November 2024

Abstract

PURPOSE
H3 K27M-mutant diffuse midline glioma (DMG) has a poor prognosis, with a median overall survival of 1 year and no proven treatments beyond radiotherapy. ONC201 (dordaviprone), a first-in-class imipridone, previously demonstrated durable responses in patients with recurrent H3 K27M-mutant DMG. The present analysis reports safety data from ONC028, a compassionate use program (CUP) for patients with previously treated H3 K27M-mutant glioma.

METHODS
ONC028 is an expanded access program that provides ONC201 monotherapy to patients with H3 K27M-mutant glioma. Eligible patients are adults or pediatric patients with H3 K27M-mutant glioma, prior therapy including at least radiation, and adequate organ function. Patients must be ineligible for enrollment in other ongoing clinical studies evaluating ONC201. ONC201 is administered orally once weekly at 625 mg or dose-equivalent based on body weight for pediatric patients. MRIs are performed every two 28-day cycles for the initial 12 months, thereafter every 2-3 cycles. Treatment continues until disease progression, unacceptable adverse events (AEs), or withdrawal of consent. Treatment may continue post-progression at the discretion of the treating physician. Bevacizumab use for radiation necrosis or symptom management is acceptable. AEs are assessed by NCI CTCAE v5.0 criteria.

RESULTS
The 422 enrolled patients include 191 adults (45.2%) and 231 children (54.7%); 87.1% had a performance score ≥60 and the most common tumor location was the pons (57.3%). Any-causality Grade ≥3 AEs have been reported in 200 patients (47.4%). Grade ≥3 treatment-related AEs (TR-AEs) were reported in 19 (4.5%) patients; the commonest was decreased lymphocyte count, occurring in 3 (0.7%) patients. Any-causality serious AEs (SAE) were reported in 43.1% (n=182) patients. There were 10 (2.4%) patients with reports of treatment-related SAEs, the commonest were ascites, nausea, vomiting, and seizure, each occurring in 2 patients (0.2%).

CONCLUSIONS
ONC028 provides expanded access to ONC201 treatment for patients with previously treated H3 K27M-mutant glioma who are ineligible for enrollment in ongoing trials of ONC201. ONC201 treatment remains well-tolerated.
NCOG-10. LONGITUDINAL MULTIDISCIPLINARY MONITORING OF NEUROCOGNITIVE FUNCTION FOR COLLOID CYST RESECTION: THE IMPACT OF SURGERY
Authors: Tosi Umberto , Sacks-Zimmerman Amanda , Villamater Francis , Spat-Lemus Jessica , Perrine Kenneth , Souweidane Mark , Bender H Allison 
Published: November 2024

Abstract
Endoscopic resection of colloid cysts, a rare pathology of the third ventricle, is now accepted clinical practice. Owing to their location proximal to numerous deep gray nuclei and to the forniceal columns, colloid cysts have always been feared to cause cognitive decline, whether operated on or not. Detailed cognitive testing before and after endoscopic resection, however, has rarely been described. Thus, out objective was to determine the neurocognitive effects of endoscopic colloid cyst resection. We analyzed formal pre- and postoperative neuropsychological testing performed in 20 patients undergoing endoscopic colloid cyst resection. Performance was compared either for each individual patient on a test-by-test basis or according to aggregated neuropsychological factor scores grouped via expert census. A clinical change was defined significant if (i) reaching statistical significance, and (ii) it was greater than 1.5 times the standard deviation of the preoperative performance distribution. Overall, 20 adult patients with colloid cysts (diameter 13.3 ± 1.3 mm) underwent matched pre- and postoperative testing generating 679 data points. No patient had a significant change in cognitive performance. When neurocognitive metrics assessing cognitive functions typically subsumed by the temporal (p = 0.35), extratemporal (p = 0.20), occipitoparietal (p = 0.31), or frontal lobes (p = 0.11), no statistically significant difference was observed between pre- and postoperative cognitive performance. No significant differences emerged when factor scores were generated according to composite score of different neurocognitive domains: attention (p = 0.32), executive function (p = 0.14), language (p = 0.98), and visuospatial function (p = 0.42). In conclusion, neuropsychological testing allows for the careful longitudinal monitoring of cognitive status and the identification of patients who may benefit from pre- and postoperative cognitive rehabilitation, and should be used as a valuable surgical psychometric marker and adjuvant. No significant cognitive decline was observed, again confirming the safety of endoscopic colloid cyst resection.
NCOG-11. FACTORS PREDICTING SPEECH AND GAIT RECOVERY IN CHILDREN WITH POST-OPERATIVE POSTERIOR FOSSA SYNDROME (PFS)
Authors: Hanzlik Emily , McAfee Stuart , Scoggins Matt , Lin Tong , Raches Darcy , Conklin Heather , Szymanek Kristin , Robinson Giles , Gajjar Amar , Onar-Thomas Arzu , Bag Asim , Khan Raja 
Published: November 2024

Abstract
Posterior fossa syndrome/cerebellar mutism syndrome is a surgical complication of posterior fossa tumor resection, especially midline tumors. Initially thought to involve complete mutism, PFS is now recognized as a complex syndrome involving loss of language (complete [PFS1] and incomplete [PFS2]). Additional symptoms include apraxia, movement disorder, motor and coordination deficits, and emotional lability. The aim of this study was to identify factors that influence delayed speech and independent gait recovery in children with PFS. We prospectively studied 73 children ≥3 years of age with medulloblastoma who developed PFS (SJMB12, NCT01878617). Enrolled children received standardized neurologic examinations and serial imaging before, during and up to five years after completion of therapy. Neurological examinations included scale for assessment and rating of ataxia (SARA), CTCAE grading of neurologic deficits, and severity of injury to the superior cerebellar peduncles (SCP) on post-operative MRI. Median time to speech recovery was 1.4 months (range 0.3-14.3); 81% had return of speech at 3 months and 97% at 12 months. On multivariable Cox regression analysis, complete mutism (HR 0.17, p&lt;0.0001) and inability to sit (HR 0.40, p=0.001) were associated with delayed speech return. Independent ambulation was regained by 80.8% at a median of 2.3 (range 0.3-71.3) months. 70% had a return of ambulation at 12 months and 77% at 24 months. On multivariable Cox regression analysis, complete mutism (HR 0.32, p=0.016), inability to sit (HR 0.30, p=0.002), SARA score (HR 0.94, p=0.002), and right SCP injury (HR 0.47, p=0.014) were significantly associated with delayed return of ambulation. Presence of mutism, inability to sit unassisted, higher SARA score, and right SCP injury at the time of PFS diagnosis are associated with time to recovery of speech/language and ambulation. Our findings have prognostic implications for families and to help identify children in need of more intensive interventions.